HSA — authorised 20 July 2023
- Marketing authorisation holder: DAIICHI SANKYO INC
- Status: likely_approved
HSA authorised Vanflyta on 20 July 2023
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. HSA authorised it on 20 July 2023.
DAIICHI SANKYO INC holds the Singaporean marketing authorisation.